The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Potentiation of crizotinib activity by fasting cycles in an ALK+ lung cancer model.
Alessio Nencioni
No relevant relationships to disclose
Irene Caffa
No relevant relationships to disclose
Lizzia Raffaghello
No relevant relationships to disclose
Fabrizio Montecucco
No relevant relationships to disclose
Michele Cea
No relevant relationships to disclose
Fiammetta Monacelli
No relevant relationships to disclose
Francesco Grossi
No relevant relationships to disclose
Franco Patrone
No relevant relationships to disclose
Patrizio Odetti
No relevant relationships to disclose
Alberto Ballestrero
No relevant relationships to disclose
Valter Longo
No relevant relationships to disclose